🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Enavate Sciences Gp - Q1 2026 13F Filings

EN

Enavate Sciences Gp, LLC

CIK: 0001953107
Address: New York New York 106 W 56Th St. Floor 8
$351.51 M
Portfolio Value
7
Assets Held
Reporting Period: Q1 2026
Filing Status:
Active
Last Updated: 08/14/2026

Portfolio Summary (Q1 2026)

View Full Portfolio Analysis

Top Buys

Q1 2026

No buy transactions available for this period

Top Sells

Q1 2026

Asset Allocation

Stocks/ETFs
-30.64%
$351.51 M 100.00%
Options
$0 0.00%
Debt
$0 0.00%
Other
$0 0.00%

Sector Allocation (Stocks)

Enavate Sciences Gp Q1 2026 Filing Summary

Enavate Sciences Gp, LLC filed its 13F report for Q1 2026 on May 15, 2026. The portfolio totaled 351.51 M reflecting a -30.64% change from the prior quarter, spanning 7 assets. The top 10 holdings comprised 100.0% of the portfolio, with Financials as the largest sector allocation. No significant position changes were reported during the quarter.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Enavate Sciences Gp’s Q1 2026 Filing

Enavate Sciences Gp submitted their Form 13F-HR for the Q1 2026 period on 05/15/2026. This was the only submission for the quarter.

In the Q1 2026 filing, Enavate Sciences Gp reported a managed portfolio value of 351.51 M, consisting of 7 individual positions.

This page displays the raw filing documents. To see which stocks Enavate Sciences Gp bought or sold during Q1 2026, please visit Enavate Sciences Gp's Portfolio Analysis page.